Biogen Inc. $BIIB Shares Acquired by Voya Investment Management LLC

Biogen logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Voya Investment Management increased its Biogen stake by 199.4% in the third quarter, adding 492,190 shares to reach 738,972 shares, valued at about $166.9 million.
  • Analyst sentiment is broadly positive: Biogen has a “Moderate Buy” consensus rating and an average price target of $254.41, with recent target increases from several firms.
  • Biogen reported quarterly earnings of $2.62 per share, beating the $1.99 consensus estimate, and revenue of $2.80 billion, up 10.6% year over year.
  • Five stocks we like better than Biogen.

Voya Investment Management LLC lifted its position in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 199.4% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 738,972 shares of the biotechnology company's stock after buying an additional 492,190 shares during the period. Voya Investment Management LLC owned 0.50% of Biogen worth $166,919,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. BlackRock Inc. purchased a new position in shares of Biogen during the 2nd quarter worth $3,453,878,000. Primecap Management Co. CA purchased a new stake in shares of Biogen in the second quarter valued at $3,274,304,000. Wellington Management Group LLP grew its position in shares of Biogen by 5.3% in the second quarter. Wellington Management Group LLP now owns 3,117,469 shares of the biotechnology company's stock valued at $673,560,000 after purchasing an additional 155,828 shares during the period. Public Sector Pension Investment Board grew its position in shares of Biogen by 10,085.8% in the third quarter. Public Sector Pension Investment Board now owns 2,466,095 shares of the biotechnology company's stock valued at $557,042,000 after purchasing an additional 2,441,884 shares during the period. Finally, Russell Investments Group Ltd. increased its stake in Biogen by 1,524.5% in the third quarter. Russell Investments Group Ltd. now owns 2,175,055 shares of the biotechnology company's stock valued at $491,301,000 after purchasing an additional 2,041,161 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company's stock.

Analyst Upgrades and Downgrades

BIIB has been the topic of several recent analyst reports. Wedbush increased their target price on Biogen from $212.00 to $225.00 and gave the stock a "neutral" rating in a research report on Thursday, October 29th. JPMorgan Chase & Co. raised Biogen from a "neutral" rating to an "overweight" rating and raised their price target for the stock from $210.00 to $300.00 in a research note on Monday, October 12th. Guggenheim lifted their price target on Biogen from $280.00 to $300.00 and gave the company a "buy" rating in a report on Monday, November 2nd. Truist Financial reaffirmed a "buy" rating and set a $260.00 price objective (up from $235.00) on shares of Biogen in a research note on Thursday, October 29th. Finally, HSBC increased their price objective on shares of Biogen from $165.00 to $175.00 and gave the stock a "reduce" rating in a report on Thursday, September 10th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Biogen currently has an average rating of "Moderate Buy" and an average price target of $254.41.

Read Our Latest Report on BIIB

Biogen Trading Down 0.3%

BIIB stock opened at $250.79 on Wednesday. The company has a market cap of $37.07 billion, a price-to-earnings ratio of 107.18, a PEG ratio of 2.85 and a beta of 0.10. The company has a quick ratio of 1.37, a current ratio of 1.95 and a debt-to-equity ratio of 0.39. The business has a fifty day simple moving average of $234.73 and a 200-day simple moving average of $205.80. Biogen Inc. has a 52 week low of $160.36 and a 52 week high of $261.00.

Biogen (NASDAQ:BIIB - Get Free Report) last issued its earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.63. Biogen had a return on equity of 9.38% and a net margin of 3.37%. The business had revenue of $2.80 billion for the quarter, compared to analyst estimates of $2.63 billion. During the same period last year, the company posted $4.81 EPS. The business's quarterly revenue was up 10.6% on a year-over-year basis. On average, equities research analysts expect that Biogen Inc. will post 12.46 EPS for the current year.

Recent Biogen Headlines

Investors following BIIB have been watching these headlines:

  • Positive Sentiment: Biogen’s Q3 growth portfolio revenue rose 49% year over year, while core pharmaceutical revenue totaled $2 billion. That growth may help offset pressure on older products and strengthen the company’s revenue outlook. Read the investor takeaways
  • Positive Sentiment: Biogen entered a research collaboration with TRIMTECH to develop small-molecule protein degraders for neurodegenerative diseases, adding an exploratory pipeline opportunity. Read the collaboration announcement
  • Neutral Sentiment: Wall Street Zen upgraded BIIB, though the available report does not specify the new rating or its rationale. Read the upgrade report

Biogen Company Profile

(Free Report)

Biogen is a biotechnology company focused on developing and commercializing medicines for neurological and rare diseases. Its areas of focus include multiple sclerosis, Alzheimer's disease, spinal muscular atrophy and Friedreich's ataxia. Its products include multiple sclerosis treatments such as Tysabri, Tecfidera and Vumerity, and Skyclarys for Friedreich's ataxia. Biogen shares rights to several medicines with other companies, including Leqembi for Alzheimer's disease with Eisai and Spinraza for spinal muscular atrophy with Ionis Pharmaceuticals.

Recommended Stories

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Biogen Right Now?

Before you consider Biogen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biogen wasn't on the list.

While Biogen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines